Literature DB >> 22403521

An Analysis of Bone Donor Deferral Rates in Scotland - a 6-Year Study.

George Galea1.   

Abstract

BACKGROUND: The Scottish National Blood Transfusion Service (SNBTS) is the main provider of tissues in Scotland. Tissue collection programmes were established in the mid-1990s, and the range of tissues collected has increased progressively over the years. MATHODS: Whilst the majority of tissues are obtained from cadaveric donations, bone is collected only from living donors who are usually patients undergoing primary hip replacement surgery (surgical donors). The bone is collected in an operating theatre, and, once stored, no further processing takes place prior to issue. Bone that fails for any reason (quality, microbiology or virological nonnegative result) is discarded.
RESULTS: The deferral rate amongst live surgical bone donors in Scotland is around 65%, and it has been slowly and progressively rising from around 55% over the past few years. This needed investigated, particularly because comparisons with blood donors show that the deferral rate amongst bone donors is more than double that of first-time blood donors (29.7%). Our processes and systems are standardised, and our cohort of bone bank nurses have all been similarly trained and competency assessed. Moreover our data collection was done in a uniform fashion. It was therefore possible to conduct a 6-year audit on bone donor deferrals. It was found that a history of transfusion (16%), history of malignancy (18%) and bone quality (26%) were the main reasons for bone donor deferrals, accounting for 60% of all deferrals.
CONCLUSIONS: When these are taken into account, the residual deferral rates become very similar numerically to blood donors. It is important to note however that there are significant differences between the blood and bone donor cohorts. This study also highlighted some of deferral reasons. Particularly malignancy is a cause of significant numbers of deferrals, and the evidence of transmissibility of malignancy through bone donation is not strong. More robust risk assessments should be undertaken prior to implementing deferral conditions.

Entities:  

Year:  2011        PMID: 22403521      PMCID: PMC3268000          DOI: 10.1159/000334892

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  6 in total

1.  The pathology of bone allograft.

Authors:  S H Palmer; C L Gibbons; N A Athanasou
Journal:  J Bone Joint Surg Br       Date:  1999-03

2.  Comparison of prevalence rates of microbiological markers between bone/tissue donations and new blood donors in Scotland.

Authors:  G Galea; B C Dow
Journal:  Vox Sang       Date:  2006-07       Impact factor: 2.144

3.  Transmission of human T-cell lymphotrophic virus type 1 by a deep-frozen bone allograft.

Authors:  L Sanzén; A Carlsson
Journal:  Acta Orthop Scand       Date:  1997-02

4.  Histopathology of retrieved allografts of the femoral head.

Authors:  S Sugihara; A D van Ginkel; T U Jiya; B J van Royen; P J van Diest; P I Wuisman
Journal:  J Bone Joint Surg Br       Date:  1999-03

5.  Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States.

Authors:  Shimian Zou; Roger Y Dodd; Susan L Stramer; D Michael Strong
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

6.  Donor exclusion in the National Blood Service Tissue Services living bone donor programme.

Authors:  F Pink; R M Warwick; J Purkis; J Pearson
Journal:  Cell Tissue Bank       Date:  2006       Impact factor: 1.522

  6 in total
  1 in total

1.  Tissue Banking and Transfusion Medicine - a Suitable Cooperation Model.

Authors:  Axel Pruß
Journal:  Transfus Med Hemother       Date:  2011-12-01       Impact factor: 3.747

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.